Abstract
There is still a need for better protection against or mitigation of the effects of ionizing radiation following conventional radiotherapy or accidental exposure. The objective of our current study was to investigate the possible roles of matrix metalloproteinase inhibitor, ilomastat, in the protection of mice from total body radiation (TBI), and the underlying protective mechanisms. Ilomastat treatment increased the survival of mice after TBI. Ilomastat pretreatment promoted recovery of hematological and immunological cells in mice after 6 Gy γ-ray TBI. Our findings suggest the potential of ilomastat to protect against or mitigate the effects of radiation.
Copyright © 2018 The Editorial Board of Biomedical and Environmental Sciences. Published by China CDC. All rights reserved.
MeSH terms
-
Acute Radiation Syndrome / blood
-
Acute Radiation Syndrome / immunology
-
Acute Radiation Syndrome / prevention & control*
-
Animals
-
Blood Cells / drug effects
-
Blood Cells / radiation effects
-
Dose-Response Relationship, Drug
-
Gamma Rays / adverse effects*
-
Hydroxamic Acids / therapeutic use*
-
Indoles / therapeutic use*
-
Matrix Metalloproteinase Inhibitors / therapeutic use*
-
Mice
-
Radiation Injuries, Experimental / blood
-
Radiation Injuries, Experimental / immunology
-
Radiation Injuries, Experimental / prevention & control*
-
Radiation-Protective Agents / therapeutic use*
-
Spleen / drug effects
-
Spleen / immunology
-
Spleen / radiation effects
-
Survival Analysis
-
Whole-Body Irradiation
Substances
-
Hydroxamic Acids
-
Indoles
-
Matrix Metalloproteinase Inhibitors
-
Radiation-Protective Agents
-
ilomastat